Great Basin Scientific Inc (GBSN) is a big mover this session, as its shares are up nearly 54%. The surge came after the molecular diagnostics company announced continued growth in the number of customers using its sample-to-result molecular diagnostic technology during the first quarter of 2015. Great Basin reported a total of 101 revenue-generating customers in the U.S. as of March 31, 2015, a 20% increase over the 84 customers reported as of the prior quarter ending December 31, 2014.
“We are pleased with our momentum in converting evaluation sites into Great Basin customers,” said in a statement Ryan Ashton, President and CEO of Great Basin Scientific. “We believe the solution we offer appeals to lab directors and technicians both for the system’s ease of use and our business model which, by placing the analyzer at no cost, allows a lab to adopt molecular diagnostic testing without any capital expenditure. We’re confident these underserved small-to medium-sized hospital labs will further embrace our unique product offering, and we look forward to building on this success throughout 2015. We are executing firmly against our plan to have 170 to 180 U.S. revenue-generating customers by the end of the year and another 40 to 45 sites in active and scheduled evaluations.”
GBSN shares recently gained $1.53 to $4.47. Over the past year, shares of Salt Lake City, Utah-based company have traded between a low of $1.48 and a high of $9.08. Shares are down 24% year-over-year ; up 82% year-to-date.